Gossamer Bio Inc GOSS

$11.50 -0.35 (-2.95%)

Valuation

Market cap
70,761,000
Revenue TTM
$48,470,000
Net income TTM
$-170,370,000
PE ratio
0.00
Forward PE
—
Profit margin
-351.50%
Debt to equity
-0.38

Trading

Volume
194,598
Avg volume
403,742
Day's range
$11.30 – $12.14
Shares out
6,111,000
Stochastic %K
74%
Beta
2.00
Analysts
Sell
Price target
$78.48

Price

Company profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial f...

Show more

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 684 1300
Website
https://www.gossamerbio.com
Address
3115 Merryfield Row, Suite 120, San Diego, United States

Latest news

Stocktwits

Juhanialainen Oct 1, 6:15 PM
$GOSS Only few dozen days before we get FDA’s approval to file the NDA. It could come before the 60 days timeline though. It will pass.
0 replies
RobertBaas1981 Oct 1, 1:28 PM
$GOSS
0 replies
RobertBaas1981 Oct 1, 10:42 AM
$GOSS Let's go up...
0 replies
Juhanialainen Oct 1, 4:07 AM
$SLS $IOVA $IBRX $GOSS $OSTX We are soft launching a comprehensive one-solution-to-cover-all-needs biotech investing service powerhouse — http://bioradar.io. This is BIG! The monthly price is insanely cheap, at least for now and you’ll get free 7 day trial to test it out risk free. I’m a partner in this 🇫🇮 based service as a Brand Ambassador & Senior Advisor and been involved in developing this service for the last few months in silence. Now the service is ready. We’ve built dozens of APIs to major data sources like Edgar for example for SEC filings, we have built-in PDUFA date calendar, dilution tracking, company cash situation, price volatility and social buzz alerts directly into your email and dozens of other features that a biotech investor needs. All in one place with just a few dollars per month. Check it out, try it free and let me know what you think.
3 replies
Finnish_boy Sep 30, 5:44 PM
$GOSS LQDA is cooked btw. I missed it under $15 bc i hesitated with ongoing litigation with UTHR. Well, stock run to $90 but now it's cooked. Remember risks always. Buying bottom with big risks works. Buying high with ongoing litigation is dangerous😂
0 replies
Finnish_boy Sep 30, 5:30 PM
$GOSS We are very early.. algos and traders love EMA20 but stock much much higher this year.. no idea about near-term.. i have full position
0 replies
Juhanialainen Sep 30, 4:23 PM
$GOSS If you look at the three month chart, it’s easy to see we’ll go back to at least $16 soon when the NDA acceptance comes. You can’t argue that it’s already priced in. Where? We’re at the literal bottom of all time! When the drop came and retail sold, many institutions kept loading the free fun coupons. I mean this is really, REALLY undervalued right now.
0 replies
Finnish_boy Sep 30, 2:58 PM
$GOSS
0 replies